Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin?

Köseoğlu V., Berberoğlu S., Karademir S., Kismet E., Yurttutan N., Demirkaya E., ...Daha Fazla

The Turkish journal of pediatrics, cilt.47, ss.17-22, 2005 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 47
  • Basım Tarihi: 2005
  • Dergi Adı: The Turkish journal of pediatrics
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.17-22
  • Anahtar Kelimeler: cardiac troponin I, doxorubicin, cardiotoxicity, LEFT-VENTRICULAR DYSFUNCTION, ANTHRACYCLINE THERAPY, CARDIOTOXICITY, CANCER, RISK
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Doxorubicin has been used in the the treatment of malignant tumors in children. Its use is limited by cardiotoxic effects beyond a cumulative dose of 450 mg/m(2). To detect cardiotoxicity at an early stage and identify patients at risk for development of cardiotoxicity are matters of concern. Recently, cardiac troponin I (cTnI) has been reported to be useful for detecting minor myocardial damage. In the present study, we investigated whether cumulative doxorubicin-related myocardial cell damage can potentially increase cTnI levels above the expected values in 22 patients treated with cumulative doxorubicin doses of 120 to 450 mg/m(2). Impaired cardiac functions were found in three patients by echocardiography, but serum CTnI levels were within the ranges expected in healthy individuals both in patients with cumulative doxorubicin doses >= 400 mg/m(2) and in patients with disturbed cardiac functions. We found no relationship between serum cTnI, cumulative dose of doxorubicin, and echocardiographical findings.